OmniAb, Inc. (OABI)

US — Healthcare Sector
Peers: CDXS  SGMO  IVVD  IMDX  CCCC  RANI  IPHA  ARMP  TARA  MIST 

Automate Your Wheel Strategy on OABI

With Tiblio's Option Bot, you can configure your own wheel strategy including OABI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol OABI
  • Rev/Share 0.1839
  • Book/Share 2.4183
  • PB 0.7195
  • Debt/Equity 0.0759
  • CurrentRatio 4.9973
  • ROIC -0.2206

 

  • MktCap 187263060.0
  • FreeCF/Share 0.2184
  • PFCF 7.4723
  • PE -3.1354
  • Debt/Assets 0.068
  • DivYield 0
  • ROE -0.2314

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 4
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors
OABI
Published: November 17, 2025 by: Business Wire
Sentiment: Neutral

EMERYVILLE, Calif. & DENVER--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) and ArrowMark Partners (“ArrowMark”) today announced the signing of a license and services agreement for novel OmniAb-derived antibody discovery programs with Mabtrx Biosciences, a wholly owned subsidiary of AMVKG LS, a joint venture (JV) between ArrowMark and Viking Global Investors (“Viking”). Under the terms of the license and services agreement, OmniAb will receive revenue for services performed as well as potential e.

Read More
image for news OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors
OmniAb, Inc. (OABI) Expected to Beat Earnings Estimates: Should You Buy?
OABI
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive

OmniAb, Inc. (OABI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More
image for news OmniAb, Inc. (OABI) Expected to Beat Earnings Estimates: Should You Buy?

About OmniAb, Inc. (OABI)

  • IPO Date 2021-09-30
  • Website https://www.omniab.com
  • Industry Biotechnology
  • CEO Matthew W. Foehr
  • Employees 114
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.